Severe chronic refractory immune thrombocytopenic purpura during childhood

A survey of physician management

Cindy E Neunert, Brianna C. Bright, George R. Buchanan

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background. Physician attitudes regarding management of children with severe chronic immune thrombocytopenic purpura (ITP) have not been recently characterized. Procedure. We designed a survey of members of the American Society of Pediatric Hematology-Oncology (ASPHO) that described a 5-year-old female with ITP for 1 year who was unresponsive to steroids, IVIG, and anti-D immune globulin and having frequent epistaxis causing interference with her daily activities. A 13-item questionnaire evaluated physician decision-making in this setting. Results. Two hundred and ninety-seven surveys (35% response rate) were returned, and 295 were evaluable. Thirty-three percent of respondents stated that they would recommend splenectomy for such a child. Of those who would not recommend splenectomy, 67% reported that they would instead treat with rituximab. If initial drug therapy failed, 47% would proceed with splenectomy. Those who reported treating with rituximab initially were more likely to recommend splenectomy following failure than those who preferred other drug therapy (P < 0.0001). Conclusions. Physician management of patients with chronic ITP is diverse. With the advent of new treatments such as rituximab and thrombopoetic agents it is critically important to compare their cost, adverse effects and efficacy with splenectomy in order to optimally guide treatment practices.

Original languageEnglish (US)
Pages (from-to)513-516
Number of pages4
JournalPediatric Blood and Cancer
Volume51
Issue number4
DOIs
StatePublished - Oct 1 2008

Fingerprint

Idiopathic Thrombocytopenic Purpura
Splenectomy
Physicians
Drug Therapy
Epistaxis
Intravenous Immunoglobulins
Hematology
Immunoglobulins
Decision Making
Steroids
Surveys and Questionnaires
Pediatrics
Costs and Cost Analysis
Therapeutics
Rituximab

Keywords

  • Immune thrombocytopenic purpura
  • Rituximab
  • Splenectomy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Severe chronic refractory immune thrombocytopenic purpura during childhood : A survey of physician management. / Neunert, Cindy E; Bright, Brianna C.; Buchanan, George R.

In: Pediatric Blood and Cancer, Vol. 51, No. 4, 01.10.2008, p. 513-516.

Research output: Contribution to journalArticle

Neunert, Cindy E ; Bright, Brianna C. ; Buchanan, George R. / Severe chronic refractory immune thrombocytopenic purpura during childhood : A survey of physician management. In: Pediatric Blood and Cancer. 2008 ; Vol. 51, No. 4. pp. 513-516.
@article{30a3a99058a04465be107c0ebf54d31a,
title = "Severe chronic refractory immune thrombocytopenic purpura during childhood: A survey of physician management",
abstract = "Background. Physician attitudes regarding management of children with severe chronic immune thrombocytopenic purpura (ITP) have not been recently characterized. Procedure. We designed a survey of members of the American Society of Pediatric Hematology-Oncology (ASPHO) that described a 5-year-old female with ITP for 1 year who was unresponsive to steroids, IVIG, and anti-D immune globulin and having frequent epistaxis causing interference with her daily activities. A 13-item questionnaire evaluated physician decision-making in this setting. Results. Two hundred and ninety-seven surveys (35{\%} response rate) were returned, and 295 were evaluable. Thirty-three percent of respondents stated that they would recommend splenectomy for such a child. Of those who would not recommend splenectomy, 67{\%} reported that they would instead treat with rituximab. If initial drug therapy failed, 47{\%} would proceed with splenectomy. Those who reported treating with rituximab initially were more likely to recommend splenectomy following failure than those who preferred other drug therapy (P < 0.0001). Conclusions. Physician management of patients with chronic ITP is diverse. With the advent of new treatments such as rituximab and thrombopoetic agents it is critically important to compare their cost, adverse effects and efficacy with splenectomy in order to optimally guide treatment practices.",
keywords = "Immune thrombocytopenic purpura, Rituximab, Splenectomy",
author = "Neunert, {Cindy E} and Bright, {Brianna C.} and Buchanan, {George R.}",
year = "2008",
month = "10",
day = "1",
doi = "10.1002/pbc.21621",
language = "English (US)",
volume = "51",
pages = "513--516",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Severe chronic refractory immune thrombocytopenic purpura during childhood

T2 - A survey of physician management

AU - Neunert, Cindy E

AU - Bright, Brianna C.

AU - Buchanan, George R.

PY - 2008/10/1

Y1 - 2008/10/1

N2 - Background. Physician attitudes regarding management of children with severe chronic immune thrombocytopenic purpura (ITP) have not been recently characterized. Procedure. We designed a survey of members of the American Society of Pediatric Hematology-Oncology (ASPHO) that described a 5-year-old female with ITP for 1 year who was unresponsive to steroids, IVIG, and anti-D immune globulin and having frequent epistaxis causing interference with her daily activities. A 13-item questionnaire evaluated physician decision-making in this setting. Results. Two hundred and ninety-seven surveys (35% response rate) were returned, and 295 were evaluable. Thirty-three percent of respondents stated that they would recommend splenectomy for such a child. Of those who would not recommend splenectomy, 67% reported that they would instead treat with rituximab. If initial drug therapy failed, 47% would proceed with splenectomy. Those who reported treating with rituximab initially were more likely to recommend splenectomy following failure than those who preferred other drug therapy (P < 0.0001). Conclusions. Physician management of patients with chronic ITP is diverse. With the advent of new treatments such as rituximab and thrombopoetic agents it is critically important to compare their cost, adverse effects and efficacy with splenectomy in order to optimally guide treatment practices.

AB - Background. Physician attitudes regarding management of children with severe chronic immune thrombocytopenic purpura (ITP) have not been recently characterized. Procedure. We designed a survey of members of the American Society of Pediatric Hematology-Oncology (ASPHO) that described a 5-year-old female with ITP for 1 year who was unresponsive to steroids, IVIG, and anti-D immune globulin and having frequent epistaxis causing interference with her daily activities. A 13-item questionnaire evaluated physician decision-making in this setting. Results. Two hundred and ninety-seven surveys (35% response rate) were returned, and 295 were evaluable. Thirty-three percent of respondents stated that they would recommend splenectomy for such a child. Of those who would not recommend splenectomy, 67% reported that they would instead treat with rituximab. If initial drug therapy failed, 47% would proceed with splenectomy. Those who reported treating with rituximab initially were more likely to recommend splenectomy following failure than those who preferred other drug therapy (P < 0.0001). Conclusions. Physician management of patients with chronic ITP is diverse. With the advent of new treatments such as rituximab and thrombopoetic agents it is critically important to compare their cost, adverse effects and efficacy with splenectomy in order to optimally guide treatment practices.

KW - Immune thrombocytopenic purpura

KW - Rituximab

KW - Splenectomy

UR - http://www.scopus.com/inward/record.url?scp=50249155246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50249155246&partnerID=8YFLogxK

U2 - 10.1002/pbc.21621

DO - 10.1002/pbc.21621

M3 - Article

VL - 51

SP - 513

EP - 516

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 4

ER -